Free Cash Flow to The Firm (FCFF)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Item | Description | The company |
---|---|---|
FCFF | Free cash flow to the firm is the cash flow available to the Bristol-Myers Squibb Co. suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. | Bristol-Myers Squibb Co. FCFF increased from 2022 to 2023 and from 2023 to 2024. |
Interest Paid, Net of Tax
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2 2024 Calculation
Interest payments, tax = Interest payments × EITR
= 1,800 × 21.00% = 378
Enterprise Value to FCFF Ratio, Current
Selected Financial Data (US$ in millions) | |
Enterprise value (EV) | 162,611) |
Free cash flow to the firm (FCFF) | 15,364) |
Valuation Ratio | |
EV/FCFF | 10.58 |
Benchmarks | |
EV/FCFF, Competitors1 | |
AbbVie Inc. | 21.52 |
Amgen Inc. | 16.18 |
Danaher Corp. | 28.55 |
Eli Lilly & Co. | 191.73 |
Gilead Sciences Inc. | 14.24 |
Johnson & Johnson | 19.12 |
Merck & Co. Inc. | 13.02 |
Pfizer Inc. | 14.99 |
Regeneron Pharmaceuticals Inc. | 16.88 |
Thermo Fisher Scientific Inc. | 24.40 |
Vertex Pharmaceuticals Inc. | — |
EV/FCFF, Sector | |
Pharmaceuticals, Biotechnology & Life Sciences | 23.57 |
EV/FCFF, Industry | |
Health Care | 23.26 |
Based on: 10-K (reporting date: 2024-12-31).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Enterprise value (EV)1 | 152,789) | 126,048) | 181,761) | 173,993) | 169,334) | |
Free cash flow to the firm (FCFF)2 | 15,364) | 13,795) | 13,100) | 16,533) | 14,563) | |
Valuation Ratio | ||||||
EV/FCFF3 | 9.94 | 9.14 | 13.87 | 10.52 | 11.63 | |
Benchmarks | ||||||
EV/FCFF, Competitors4 | ||||||
AbbVie Inc. | 20.05 | 14.89 | 12.15 | 13.18 | 13.95 | |
Amgen Inc. | 15.35 | 22.22 | 16.01 | 15.82 | 14.51 | |
Danaher Corp. | 28.93 | 36.34 | 25.74 | 28.25 | 30.66 | |
Eli Lilly & Co. | 200.93 | 655.33 | 59.14 | 38.37 | 39.01 | |
Gilead Sciences Inc. | 14.50 | 13.41 | 13.58 | 8.42 | 13.60 | |
Johnson & Johnson | 18.16 | 19.30 | 23.80 | 21.25 | 20.75 | |
Merck & Co. Inc. | 13.24 | 37.84 | 19.09 | 23.27 | 34.12 | |
Pfizer Inc. | 15.33 | 32.24 | 9.15 | 8.40 | 21.74 | |
Regeneron Pharmaceuticals Inc. | 19.30 | 23.99 | 17.96 | 9.81 | 25.74 | |
Thermo Fisher Scientific Inc. | 26.13 | 28.85 | 31.61 | 33.14 | 26.14 | |
Vertex Pharmaceuticals Inc. | — | 29.45 | 16.68 | 22.47 | 16.00 | |
EV/FCFF, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | 23.57 | 27.24 | 17.95 | 16.12 | 19.74 | |
EV/FCFF, Industry | ||||||
Health Care | 22.99 | 24.06 | 17.76 | 17.08 | 18.03 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
3 2024 Calculation
EV/FCFF = EV ÷ FCFF
= 152,789 ÷ 15,364 = 9.94
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/FCFF | Enterprise value to free cash flow to the firm is whole company valuation indicator. | Bristol-Myers Squibb Co. EV/FCFF ratio decreased from 2022 to 2023 but then slightly increased from 2023 to 2024. |